To determine the cytogenetic and genotoxic risk associated with therapeutic exposure to
131I (3.7 GBq) in 50 patients with differentiated thyroid carcinoma, we estimated the …

A multicentre study was undertaken to assess the cytogenetic damage to peripheral blood
lymphocytes in 31 patients treated with 131I for thyrotoxicosis using the cytokinesis-blocked …

GBq 131I. Repeated administrations of1311delivered the same dose each time, resulting in
a cumulative dose from 1-3.5 Gy in the patients who had two to seven treatments. However …

The study aimed to investigate whether the determination of chromosome aberrations in
circulating blood lymphocytes could be useful to assess whole-body exposure from …

Results: The mean number (mean ±sd) of micronuclei after treatment was significantly
increased (p< 0.05) as compared to control subjects (15.7 ±2.7 vs. 5.4 ±1.4). Since there …

This study set out to investigate chromosomal damage in peripheral blood lymphocytes of
thyroid cancer patients receiving 131 I for thyroid remnant ablation or treatment of metastatic …

To provide quantitative data on the risk of thyroid cancer after exposure to131 I, 34,104
patients administered131 I for diagnostic purposes were followed for up to 40 years. The …

To determine the genotoxic risk associated with therapeutic exposure to 131I, we studied the
presence of micronuclei (MN) in binucleated peripheral blood lymphocytes of a group of 22 …

Iodine-131 for Differentiated Thyroid Carcinoma Page 1 Biological Dosimetry in Patients Treated
with Iodine-131 for Differentiated Thyroid Carcinoma R. M’Kacher, JD Legal, M. Schlumbcrger …

The purpose of this study was to compare cytogenetic data in a patient before and after
treatment with radioiodine to evaluate the assays in the context of biological dosimetry. We …